Last reviewed · How we verify
Pandel (HYDROCORTISONE PROBUTATE)
Pandel (generic name: HYDROCORTISONE PROBUTATE) is a Corticosteroid Small molecule drug developed by ANI Pharmaceuticals. It is currently FDA-approved (first approved 1997).
Pandel (Hydrocortisone probutate) is a corticosteroid medication originally developed by Fougera Pharmaceuticals and currently owned by Ani Pharmaceuticals. It targets the glucocorticoid receptor and is used to treat various skin conditions. Pandel is a small molecule drug that was FDA-approved in 1997 and is now off-patent. As a corticosteroid, it reduces inflammation and immune responses in the body. However, its commercial status and pharmacokinetic properties are not well-documented.
At a glance
| Generic name | HYDROCORTISONE PROBUTATE |
|---|---|
| Sponsor | ANI Pharmaceuticals |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia (PHASE1)
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pandel CI brief — competitive landscape report
- Pandel updates RSS · CI watch RSS
- ANI Pharmaceuticals portfolio CI
Frequently asked questions about Pandel
What is Pandel?
Who makes Pandel?
What is the generic name of Pandel?
What drug class is Pandel in?
When was Pandel approved?
What development phase is Pandel in?
What does Pandel target?
Related
- Drug class: All Corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: ANI Pharmaceuticals — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing